Enovis Corp SEC Filings

Enovis CORP SVP and Chief Financial Officer Phillip Ben Berry reported a tax-related share withholding, not an open-market sale. On this Form 4, 7,774 shares of common stock were withheld by the company at $25.99 per share to satisfy tax obligations tied to restricted stock units. After this withholding, Berry directly holds 150,822 shares of Enovis common stock.

Enovis Corporation reported higher sales and a much smaller loss for the three months ended April 3, 2026. Net sales rose to $589.2 million from $558.8 million, led by growth in the Reconstructive segment and modest gains in Prevention & Recovery.

Gross profit increased to $365.5 million, lifting gross margin to 62.0% from 59.4% as product mix and lower inventory step-up charges helped profitability. Net loss narrowed to $8.5 million, or $0.15 per share, compared with a $55.7 million loss a year earlier, helped by the absence of a prior one-time royalty buyout expense.

Adjusted EBITDA, a key non-GAAP metric, improved to $103.6 million from $87.1 million, with margins rising to 17.6%. Cash flow from operating activities turned positive at $24.0 million versus a slight outflow in the prior year, while the company ended the quarter with $33.1 million in cash and total debt of $1.33 billion.

Enovis Corporation reported higher first-quarter 2026 sales while remaining loss-making on a GAAP basis but stronger on adjusted metrics. Net sales were $589.2 million, up 5.4% year over year and 3.3% organically, driven by 10.8% reported growth in Reconstructive, while Prevention & Recovery was flat.

The company posted a GAAP net loss of $8.5 million, a net margin of (1.4)%, but generated adjusted net income from continuing operations of $51.6 million, or $0.89 per diluted share, up from $0.65 a year earlier. Adjusted EBITDA was $103.6 million, representing a 17.6% margin versus 15.6% last year.

Enovis reaffirmed its full-year 2026 outlook, expecting revenue of about $2.31–$2.37 billion, incorporating 4–6% organic growth, adjusted EBITDA of $425–$435 million, adjusted EPS of $3.52–$3.73, and free cash flow conversion of 25% or higher.

Enovis Corp reported a Schedule 13G ownership disclosure by Vanguard Capital Management. Vanguard reports 2,995,321 shares beneficially owned, representing 5.23% of Enovis common stock. The filing shows sole dispositive power over 2,995,321 shares and sole voting power for 442,970 shares. The report is signed by Vanguard's Head of Global Fund Administration.

Enovis Corp reported that Vanguard Portfolio Management beneficially owned 3,906,658 shares of Common Stock, representing 6.82% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power for 3,906,658 shares and sole voting power for 98,029 shares. The Schedule 13G filing was signed on 04/29/2026.

Enovis CORP executive Laura Lee Singleton, SVP and Chief HR Officer, filed an initial ownership report. She directly holds 15,552 shares of common stock and an employee stock option covering 1,091 underlying shares at an exercise price of $57.62 per share, expiring on February 27, 2030. The filing also notes unvested restricted stock units and that the option grant vested in three equal installments in 2024, 2025 and 2026.

Enovis Corporation is holding a virtual 2026 annual stockholder meeting on May 19, 2026, where investors will vote on electing ten directors, ratifying Ernst & Young as auditor, an advisory say‑on‑pay vote and an amendment to the 2020 Omnibus Incentive Plan.

For 2025, Enovis reports adjusted earnings per share of $2.24 and adjusted EBITDA of $401.8 million. Annual bonuses for named executives were funded at a company performance factor of 92.2% of target, reflecting net sales and adjusted EBITDA outcomes below internal goals. Long‑term incentives are split between time‑based RSUs and PRSUs tied to relative total shareholder return with a three‑year performance period and a cap at target if absolute TSR is negative.

The proxy highlights a largely independent, MedTech‑experienced board, mandatory director retirement at age 75, robust stock ownership guidelines, a clawback policy, and restrictions on hedging and pledging. In the 2025 advisory vote, approximately 98% of votes cast supported executive pay, which the compensation committee viewed as validation of its pay‑for‑performance framework.

Enovis CORP director Christine Ortiz received a stock grant that increased her direct ownership. On March 31, 2026, she was granted 770 shares of Enovis common stock at a stated price of $0.00 per share, reflecting a compensation-related award rather than an open-market purchase.

After this grant, Ortiz directly holds 15,665 shares of Enovis common stock. The filing shows no accompanying sales or derivative exercises, so this transaction represents a small, routine increase in her equity stake through non-derivative stock compensation.

Enovis Corp received an amended Schedule 13G/A from The Vanguard Group reporting 0 shares beneficially owned, representing 0% of Common Stock as stated in the filing. The amendment explains an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries report holdings separately.

The filing lists the filer address and certifies no sole or shared voting or dispositive power over Enovis shares. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.